Glycoengineering in CHO Cells: Advances in Systems Biology

Glycoengineering in CHO Cells: Advances in Systems Biology IntroductionChinese hamster ovary (CHO) cells are the most widely used host for manufacturing complex biopharmaceuticals due to their ability to replicate folding and post‐translational modifications, including glycosylation patterns, found in human proteins. CHO cells also grow robustly in suspension in serum‐free media and have a long history of regulatory approval and an established track record for producing safe, efficacious products. In 1987, the US Food and Drug Administration (FDA) approved the first CHO‐derived recombinant protein, tissue plasminogen activator (t‐PA) for use as a therapeutic. Since this approval, CHO cells have been the clearly preferred choice for commercial production of glycoprotein biologics, ranging from antibodies to hormones to cytokines. In 2016, 5 of the top 10 biopharmaceuticals were produced in CHO cells while 10 out of the 15 biopharmaceuticals approved by the FDA in 2016 were produced in CHO cells, including 3 biosimilars.Correct glycan structures are crucial for potency and control of pharmacokinetic and pharmacodynamic properties of glycoprotein biologics and therapeutic carbohydrates. Protein glycosylation and synthesis of the glycosaminoglycan (GAG) portion of proteoglycans are non‐templated, and thus, significant heterogeneity can arise from organism to organism, cell type to cell type, and even between different culture conditions. While CHO cells produce http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biotechnology Journal Wiley

Glycoengineering in CHO Cells: Advances in Systems Biology

Loading next page...
 
/lp/wiley/glycoengineering-in-cho-cells-advances-in-systems-biology-40U0JANYOu
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISSN
1860-6768
eISSN
1860-7314
D.O.I.
10.1002/biot.201700234
Publisher site
See Article on Publisher Site

Abstract

IntroductionChinese hamster ovary (CHO) cells are the most widely used host for manufacturing complex biopharmaceuticals due to their ability to replicate folding and post‐translational modifications, including glycosylation patterns, found in human proteins. CHO cells also grow robustly in suspension in serum‐free media and have a long history of regulatory approval and an established track record for producing safe, efficacious products. In 1987, the US Food and Drug Administration (FDA) approved the first CHO‐derived recombinant protein, tissue plasminogen activator (t‐PA) for use as a therapeutic. Since this approval, CHO cells have been the clearly preferred choice for commercial production of glycoprotein biologics, ranging from antibodies to hormones to cytokines. In 2016, 5 of the top 10 biopharmaceuticals were produced in CHO cells while 10 out of the 15 biopharmaceuticals approved by the FDA in 2016 were produced in CHO cells, including 3 biosimilars.Correct glycan structures are crucial for potency and control of pharmacokinetic and pharmacodynamic properties of glycoprotein biologics and therapeutic carbohydrates. Protein glycosylation and synthesis of the glycosaminoglycan (GAG) portion of proteoglycans are non‐templated, and thus, significant heterogeneity can arise from organism to organism, cell type to cell type, and even between different culture conditions. While CHO cells produce

Journal

Biotechnology JournalWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off